Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMAG PHARMACEUTICALS, INC.AMAG · Entity 145305 | Director · President & CEO | March 02, 2020 | March 04, 2020 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 09, 2026 | June 11, 2026 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMAG PHARMACEUTICALS, INC.
Report date March 02, 2020 · Filed March 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 424,612 |
Reported balance
After 2020-03-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-03-02 · Tax withholding · Disposed 4,451 · Balance 424,612 F1: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 15,165 restricted stock units ("RSUs") on March 2, 2020. F2: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 55,000 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 15,165 restricted stock units ("RSUs") on March 2, 2020.
F2: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 55,000 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017.
Atara Biotherapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,188 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 12,000 · Balance 34,188 F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
MACROGENICS INC
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,750 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 114,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002921 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,188 F1 · shares: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001214939-26-000002 · wk-form4_1779308039.xml · derivative · entry 4 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214939-26-000002 · wk-form4_1779308039.xml · derivative · entry 3 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214939-26-000002 · wk-form4_1779308039.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. F2 · derivative.expiration_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214939-26-000002 · wk-form4_1779308039.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 20:19 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 49,500 | $1.49 | $73,755.00 |
DisclosureSEC source: 0001214939-25-000004 · wk-form4_1755807584.xml · nonDerivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.50. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 20:19 UTC | MACROGENICS INC MGNX · Entity 6104 | PurchaseCommon Stock | 50,500 | $1.52 | $76,760.00 |
DisclosureSEC source: 0001214939-25-000004 · wk-form4_1755807584.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.59. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002137 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,188 F1 · shares: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001125345-25-000082 · wk-form4_1747944160.xml · derivative · entry 4 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000082 · wk-form4_1747944160.xml · derivative · entry 3 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000082 · wk-form4_1747944160.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. F2 · derivative.expiration_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-25-000082 · wk-form4_1747944160.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:16 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001125345-24-000128 · wk-form4_1716498992.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:16 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000128 · wk-form4_1716498992.xml · derivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000108 · wk-form4_1716410055.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. F2 · derivative.expiration_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000108 · wk-form4_1716410055.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 22:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001059 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,000 F1 · shares: These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service. Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 23:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 100,000 | $0.25 | $25,330.00 |
DisclosureSEC source: 0000905148-23-001450 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,000 F1 · price: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2489 to $0.265. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:53 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000095 · wk-form4_1685739198.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:53 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001125345-23-000095 · wk-form4_1685739198.xml · derivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 79,500 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001140361-23-028149 · form4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2033-05-30 F2 · derivative.exercise_date: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-028149 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 F1 · shares: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001140361-22-024165 · form4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-024165 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 23, 2022 Filed May 24, 2022 20:29 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001125345-22-000073 · wf-form4_165342417498958.xml · derivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2032-05-23 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 23:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001140361-21-020444 · form4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 23:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-020444 · form4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 24,500 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001209191-20-037368 · doc4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2030-06-15 F2 · derivative.exercise_date: The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037368 · doc4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 F1 · shares: These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:50 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 4,451 | $7.75 | $34,495.25 |
DisclosureSEC source: 0001104659-20-029292 · a4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,612 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 15,165 restricted stock units ("RSUs") on March 2, 2020. F2 · balance_after: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 55,000 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 16:50 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 3,033 | $8.84 | $26,811.72 |
DisclosureSEC source: 0000792977-20-000021 · wf-form4_158266739872552.xml · nonDerivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,063 F2 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,333 restricted stock units on February 25, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 16:50 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 2,960 | $9.50 | $28,120.00 |
DisclosureSEC source: 0000792977-20-000021 · wf-form4_158266739872552.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,096 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 10,002 restricted stock units on February 23, 2020. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-19-039763 · doc4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-26 F2 · derivative.exercise_date: The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039763 · doc4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 09, 2019 Filed May 9, 2019 16:16 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | PurchaseCommon Stock | 10,000 | $10.70 | $107,000.00 |
DisclosureSEC source: 0000792977-19-000088 · wf-form4_155743296909414.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,056 F1 · price: The shares purchased on this date were purchased in multiple transactions. The actual purchase prices range from $10.59 to $10.93, inclusive. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each price. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:10 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 4,467 | $14.76 | $65,932.92 |
DisclosureSEC source: 0000792977-19-000048 · wf-form4_155182741138125.xml · nonDerivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,056 F2 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 15,165 restricted stock units on March 2, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:10 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 3,535 | $14.76 | $52,176.60 |
DisclosureSEC source: 0000792977-19-000048 · wf-form4_155182741138125.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,523 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 12,003 restricted stock units on March 1, 2019. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:28 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $15.51 | Not disclosed |
DisclosureSEC source: 0000792977-19-000030 · wf-form4_155131011892355.xml · derivative · entry 3 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-25 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:28 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 132,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000030 · wf-form4_155131011892355.xml · nonDerivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,058 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:28 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000030 · wf-form4_155131011892355.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,058 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020. F3 · price: Not applicable. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 17:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 2,957 | $15.51 | $45,863.07 |
DisclosureSEC source: 0000792977-19-000025 · wf-form4_155122135867402.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,058 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 9,999 restricted stock units on February 23, 2019. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 17:17 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0000792977-18-000055 · wf-form4_153376303702341.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,015 F1 · kind: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| June 14, 2018 Filed Jun 19, 2018 01:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-18-038443 · doc4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F2 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Jun 19, 2018 01:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038443 · doc4.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 07:21 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 20,000 | $25.00 | $500,000.00 |
DisclosureSEC source: 0000792977-18-000025 · wf-form4_152819765533895.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,015 F1 · kind: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:24 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001179110-18-003696 · edgar.xml · derivative · entry 4 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-03-02 F3 · price: Not applicable. F6 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:24 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 10,546 | $21.00 | $221,466.00 |
DisclosureSEC source: 0001179110-18-003696 · edgar.xml · nonDerivative · entry 3 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,015 F5 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 9,999 RSUs on February 23, 2018, 10,002 RSUs on February 26, 2018, 3,900 RSUs on February 27, 2018, and 11,999 RSUs on March 1, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 10,546 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:24 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 45,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003696 · edgar.xml · nonDerivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,561 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:24 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 45,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003696 · edgar.xml · nonDerivative · entry 1 HEIDEN WILLIAM K · CIK 0001214939 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,061 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on March 2, 2019. F3 · price: Not applicable. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001209191-17-039236 · doc4.xml · derivative · entry 2 HEIDEN WILLIAM K · CIK 0001214939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2024-06-08 F2 · derivative.exercise_date: The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.